Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva R&D Spending Target Raised To 7.5% Of Sales

Executive Summary

Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12

You may also be interested in...

Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008

Roche spending increases on pharmaceutical research and development will continue to outpace sales gains in 2008, company executives said during the firm's fourth quarter financial review Jan. 30

Teva Bulks Up Biopharma With $400 Million CoGenesys Acquisition

Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22

Teva Throws Wyeth Year-End Curve Ball With Launch Of Generic Protonix

Teva's launch of a generic version of Wyeth's proton pump inhibitorProtonix (pantoprazole) means that Wyeth must quickly decide how much faith to place in its patent as it negotiates a potential settlement

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts